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and ULBP proteins (Bauer et al., 1999; Cosman et al.,
2001) in humans and the Rae1 and H60 families in mice
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(Nomura et al., 1996; Malarkannan et al., 1998; CerwenkaDepartment of Molecular and Cell Biology and
et al., 2000; Diefenbach et al., 2000). All of the identifiedCancer Research Laboratory
ligands are distantly related to MHC class I proteins.489 Life Sciences Addition
MICA/B and Rae1 proteins are not expressed by mostUniversity of California, Berkeley
normal cells in postnatal humans or mice, respectively,Berkeley, California 94720
but are upregulated strongly in many types of tumor
cells (Groh et al., 1996; Zou et al., 1996; Cerwenka et
al., 2001; Diefenbach et al., 2001). In addition, MICA/BSummary
proteins are upregulated in virally infected cells (Groh
et al., 2001). The upregulation of MIC and Rae1 in tumorLittle is known concerning the stimulatory receptors
cells suggests a role for NKG2D in stimulating NK cellresponsible for tumor cell lysis by NK cells. We gener-
responses against tumor cells. Indeed, tumor cellsated a monoclonal antibody specific for murine
transduced to express high levels of NKG2D ligands areNKG2D in order to investigate its function. Blocking
attacked by NK cells in vitro (Bauer et al., 1999; Cer-of NKG2D inhibited natural cytotoxicity of all tumor
wenka et al., 2000; Diefenbach et al., 2000). Furthermore,cells tested that express ligands for the receptor.
tumor cells transduced with NKG2D ligands are vigor-Staining analysis showed that NKG2D is also ex-
ously rejected by syngeneic mice (Cerwenka et al., 2001;pressed by activated CD8 T cells and macrophages,
Diefenbach et al., 2001) and stimulate the developmentand subsets of TCR and NK1.1 T cells. Contradict-
of potent protective T cell immunity (Diefenbach et al.,ing reports that NKG2D is solely a costimulatory re-
2001). While these studies implicate NKG2D as a recep-ceptor, we observed that cross-linking of NKG2D di-
tor involved in tumor cell recognition, direct evidence ofrectly stimulates NK cells and activated macrophages.
its participation in natural killing of untransfected tumorIn contrast, NKG2D costimulates activated CD8 T
cells is lacking.cells. Thus, NKG2D engagement directly stimulates
NKG2D expression is not limited to NK cells. InitialNK cells and macrophages, costimulates CD8 T cells,
reports indicated that NKG2D is expressed by all humanand plays a substantial role in natural killing.
CD8 T cells and  T cells (Bauer et al., 1999). In mice,
studies with a polyclonal antibody and RT-PCR indi-Introduction
cated that activated but not resting CD8 T cells and
macrophages express NKG2D (Diefenbach et al., 2000).Natural killer (NK) cell reactivity with tumor cells and
RT-PCR experiments suggest expression in murine infected cells is determined by a balance between stimu-
T cells in the skin (Girardi et al., 2001). Expression bylatory and inhibitory receptor interactions. NK cells ex-
various other types of  and  T cells has not beenpress inhibitory receptors from three known families that
investigated. Furthermore, cell surface expression ofdirectly recognize MHC class I molecules: the killer cell
murine NKG2D by any of these cell types has not beenimmunoglobulin-like receptors (KIRs) in humans, the
confirmed with monoclonal antibodies.CD94/NKG2A lectin-like receptors found in both hu-
A key issue with respect to NKG2D function is whethermans and rodents, and the Ly49 receptor family found
it provides a stimulatory or costimulatory signal to re-
in rodents (Moretta et al., 1996; Lanier, 1998; Raulet et
sponding cells. Analysis of human NK cells has led to
al., 2001). Interactions between these inhibitory recep-
the conclusion that NKG2D pairs exclusively with the
tors and self class I molecules are important in the regu- signaling subunit DAP10 (Wu et al., 1999, 2000). Other
lation and self-tolerance of NK cells. NK cell stimulatory receptors pair with distinct signaling
The frequent downregulation of MHC class I mole- subunits such as DAP12, FcRI, and CD3, all of which
cules in tumor cells explains, in part, their sensitivity contain one or more immunoreceptor tyrosine-based
to NK cells. However, numerous NK-susceptible tumor activation motifs (ITAM) in their cytoplasmic domains
target cell lines express normal levels of MHC class I (Vivier and Daeron, 1997; Moretta et al., 2001). In con-
molecules (Dennert et al., 1988; Correa et al., 1994), trast, DAP10 lacks a discernable ITAM and contains
suggesting the existence of other determinants of NK instead a YxxM motif, implicated in binding to the p85
sensitivity. Recently, evidence has accumulated that NK subunit of PI-3 kinase. Indeed, tyrosine phosphorylated
cells are also regulated by stimulatory receptors, some DAP10 was shown to coimmunoprecipitate with p85
of which recognize ligands that are upregulated specifi- from lysates of human NK cells (Wu et al., 1999).
cally by tumor cells (reviewed in Moretta et al., 2001). The YxxM motif is also found in the cytoplasmic do-
The best characterized example to date is the NKG2D main of the CD28 and ICOS molecules, where it is
receptor and its ligands (Diefenbach and Raulet, 2001). thought to impart a costimulatory signal as opposed to
NKG2D is a lectin-like stimulatory receptor originally the directly stimulatory signal typically transmitted by
identified in NK cells. Various families of cell surface receptors that contain ITAMs (Chambers, 2001). In line
with these findings, studies of human CD8 T cells sug-
gest that NKG2D engagement is costimulatory in con-1Correspondence: raulet@uclink4.berkeley.edu
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junction with T cell antigen receptor engagement (Groh
et al., 2001). The situation is less clear-cut in the case
of NK cells. Transfection of NKG2D ligands into several
NK-resistant target cell lines was sufficient to render the
cells sensitive to NK cells (Bauer et al., 1999; Cerwenka
et al., 2000; Diefenbach et al., 2000, 2001). Similarly,
such transfected tumor cell lines were able to stimulate
nitric oxide synthesis and TNF transcription by acti-
vated macrophages (Diefenbach et al., 2000). NKG2D
engagement may therefore signal differently in NK cells
and macrophages compared to T cells, resulting in di-
rect cellular activation. Alternatively, it is possible that
the transfected tumor cells also express unknown li-
gands for undefined stimulatory receptors expressed
by NK cells and macrophages. In this case, NKG2D
engagement may provide a costimulatory signal that
dramatically amplifies the response.
Here we report the derivation of a monoclonal anti-
body specific for mouse NKG2D. We have been able to
definitively identify the cell types expressing the recep-
tor in mice and address two important questions regard-
ing NK cell function: the contribution of the NKG2D re-
ceptor in natural killing of tumor cells and the capacity




A monoclonal antibody specific for NKG2D, MI-6, was
used to examine the cell surface expression of NKG2D
on a variety of cell types. Fc receptor binding was pre-
vented by preincubation of the cells with a FcR-specific
mAb. Nearly all NK1.1CD3 splenocytes and lympho-
kine activated killer (LAK) cells from adult C57Bl/6J (B6)
mice expressed NKG2D (Figure 1A). Small percentages
of NK1.1 cells present in the NKG2D-negative quad-
rants appeared, nevertheless, to express low levels of
NKG2D compared to the control NK1.1 cells. Compara-
ble staining was observed with NK cells from a variety
of other mouse strains, including BALB.B, BALB/c, DBA-
2/J, DBA-2Ncr, CBA/J, CD-1, 129/Tac, FVB/NJ, B10.A/
SgSnJ, and B10.BR/J mice (data not shown). Substantial
NKG2D expression was detected as early as day 15 of
gestation on NK cells extracted from the fetal thymus,
indicating that the receptor is expressed early in NK
cell development (Figure 1B). The receptor was also
expressed by approximately 70% of NK1.1 T cells pres-
ent in the thymus (Figure 1A) or spleen (data not shown)
of B6 mice. NKG2D expression occurred in a similar
percentage of CD4, CD8, and CD4CD8 NK1.1 T
cells (data not shown).
Figure 1. NKG2D Expression by NK Cells, NK1.1 T Cells, and 
Cells
(A) Nearly all NK cells express NKG2D. Top: staining, with MI-6 mAb
NK cells were initially enriched by treatment with anti-CD24 andversus anti-NK1.1, of B cell-depleted splenocytes as a source of
freshly isolated NK cells (left) or IL-2 activated NK cells (4 day LAK complement. A representative analysis of three performed is de-
picted.cells, right). Note that after 4 days in LAK culture conditions, some
NK1.1 cells express NKG2D; a separate analysis (data not shown) (C) Selective expression of NKG2D by TCR cells. Top: NKG2D
expression by a subset of CD44 TCR cells from the spleen (left)showed that these cells were CD8. Bottom: comparison of gated
splenic NK cells (NK1.1CD3) and gated thymic NK1.1CD3 cells. or adult thymus (right). Bottom: NKG2D expression by TCR den-
dritic epidermal cells (DEC) but not by TCR intestinal intraepithe-Representative analyses of six performed are depicted.
(B) NKG2D is expressed early in NK cell ontogeny. Gated NK cells lial lymphocytes (IEL). The 4.5% of intestinal IELs that express
NKG2D but not TCR also express NK1.1 (data not shown). Afrom the E15 fetal thymus or from the spleen of newborn (nb),
3-week-old, and 8-week-old B6 mice were compared. In all cases, representative analysis of five performed is depicted.
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Figure 2. Induced Expression of NKG2D by
CD8 but Not CD4  T Cells
Representative results of three or four experi-
ments performed are depicted.
(A) Spleen cells were stimulated for the indi-
cated number of days in 96-well plates
coated with 5 	g/ml anti-TCR mAb before
analysis of NKG2D surface expression on
gated CD8 and CD4 T cells.
(B) Splenocytes from OT-1 transgenic mice
were stimulated for the indicated number
of days with irradiated B6 splenocytes that
had been pulsed with ovalbumin peptide
(SIINFEKL) before analysis of NKG2D expres-
sion on gated transgene-expressing (V2) T
cells.
(C) At the indicated times after infection of
B6 mice with LCMV, gated splenic CD8 T
cells were analyzed for NKG2D expression as
well as for expression of TCRs specific for
the GP33/Db viral epitope (using the corre-
sponding tetramers). For analysis of second-
ary infection, virus-immune mice were rein-
fected with LCMV and analyzed 5 days later.
MI-6 mAb stained approximately 25% of splenic  T trast, NKG2D was not significantly expressed by acti-
vated conventional CD4 T cells at any time point testedcells and 5% of thymic  T cells (Figure 1C). The
NKG2D  T cells all expressed the memory/activation (Figure 2A).
NKG2D was also upregulated by CD8 T cells acti-marker CD44, but many CD44 T cells did not express
NKG2D. NKG2D was expressed by a similar percentage vated with antigens in vitro or in vivo. Stimulation of
CD8 T cells from ovalbumin peptide-specific OT-1of V2 and V1.1  T cells, the major V-defined
subsets in the spleen (data not shown). Interestingly, transgenic mice with peptide-pulsed splenocytes in
vitro led to NKG2D expression by a subpopulation ofNKG2D was expressed by essentially all  T cells in
the skin (dendritic epidermal T cells, or DECs) (Figure transgene-expressing (V2) T cells on day 3 of activa-
tion and by nearly all the cells by day 5 (Figure 2B). To1C). In contrast, intestinal intraepithelial  T cells (IEL)
did not express NKG2D (Figure 1C). study NKG2D induction in vivo, B6 mice were infected
with lymphocytic choriomeningitis virus (LCMV), and an-Freshly isolated CD8 and CD4 splenic  T cells
from nonimmune mice did not stain with MI-6 mAb, tigen-specific CD8 T cell populations were examined
using fluorochrome-conjugated MHC class I tetramersconfirming previous findings that naive T cells in mice
do not express NKG2D (Figure 2A) (Diefenbach et al., loaded with viral epitopes. At the peak of the immune
response (day 9), nearly all CD8 T cells specific for the2000). After activation in vitro with plate-bound anti-
TCR antibody, NKG2D expression was detectable on GP33 or NP396 viral peptides had upregulated NKG2D
(Figure 2C, and data not shown). An interesting findingthe surface of CD8 T cells within 2 days (Figure 2A).
The levels continued to increase, reaching high uniform was that NKG2D expression remained high on virus-
specific memory T cells even 8 months after infectionlevels by the fifth day of activation. The unimodal stain-
ing pattern indicated that NKG2D was upregulated in and was retained on the virus-specific T cells re-
sponding to a secondary infection. NKG2D expressionCD8 T cells that did not previously express it. In con-
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was also induced on many CD8 T cells that did not
stain with these two tetramers. Most of these cells are
probably specific for other viral epitopes, though some
may represent “bystander” CD8 T cells that are partially
activated during LCMV infection.
To examine NKG2D expression by macrophages, we
employed F(ab
)2 fragments of MI-6 mAb to prevent in-
teractions with Fc receptors. MI-6 F(ab
)2 failed to stain
bone marrow-derived macrophages that had been cul-
tured for 1–3 days in medium alone or with the addition
of TNF (Figure 3A). However, macrophages that had
been cultured for 1–3 days in the presence of LPS, IFN-,
or IFN-/ exhibited clear staining with MI-6 F(ab
)2, as
compared to control polyclonal rat F(ab
)2 (Figure 3A).
Staining was completely blocked if the MI-6 F(ab
)2 were
preincubated with recombinant NKG2D protein. Surface
expression of NKG2D was detectable after 1 day in cul-
ture and increased on days 2 and 3 of stimulation. Similar
results were seen for macrophages isolated from the
peritoneum after thioglycollate induction (data not
shown). Accordingly, Northern blot analysis revealed
that NKG2D mRNA was absent in bone marrow-derived
macrophages that had been cultured with TNF or no
addition, but was clearly detectable in macrophages
that had been cultured with LPS, IFN-, or especially
IFN-/ (Figure 3B).
Cross-Linking of NKG2D with MI-6 mAb Activates NK
Cells and Macrophages, but Not CD8 T Cells
The capacity of MI-6 mAb to stimulate NKG2D cells
was assessed. The addition of MI-6 mAb to FcR Daudi
target cells enhanced lysis of these cells by LAK cells,
suggesting that the antibody mediates redirected lysis
when bridged to a target cell (Figure 4A). Although these
data are consistent with direct stimulation of NK cells
by NKG2D, it remained possible that additional receptor/
ligand interactions between the NK cell and the target
cell were necessary for realization of MI-6-mediated cy-
totoxicity.
To investigate whether NKG2D engagement alone im-
Figure 3. NKG2D Expression by Macrophages Is Induced by Inter-parts a sufficient stimulatory signal, we determined
ferons or LPS but Not TNFwhether cells could be activated by cross-linking
(A) Bone marrow-derived macrophages (98% F4/80 and CD11b)NKG2D with MI-6 mAb. In a similar setting, antibodies
were cultured without stimulation or with 20 ng/ml LPS, 10 ng/mlspecific for the costimulatory CD28 or ICOS receptors
IFN-, 1000 U/ml IFN-/, or 1 ng/ml TNF. After 24–72 hr, the cells
on T cells do not provide a sufficient stimulatory signal, were examined for NKG2D surface expression using MI-6 F(ab
)2
but do provide signals that synergistically stimulate the fragments. Shaded, MI-6 F(ab
)2; solid open, control F(ab
)2; dotted
open, MI-6 F(ab
)2 preincubated with recombinant NKG2D protein.cells in conjunction with engagement of the ITAM-con-
(B) Northern blot analysis of NKG2D (top) or actin (bottom) tran-taining T cell receptor complex (Harding et al., 1992;
scripts in bone marrow-derived macrophages that had been cul-Hutloff et al., 1999). Incubation with MI-6 followed by
tured in vitro for 6 days with L-CSF (to stimulate macrophage prolif-cross-linking with secondary anti-rat IgG Abs resulted
eration), which was supplemented on the last 2 days of culture with
in a Ca2 flux in many IL-2 cultured NK cells (LAK cells); LPS, IFN-, IFN-, TNF, or no addition as indicated.
control rat IgG or the nonstimulatory DX5 mAb had no
effect (Figure 4B, and data not shown). These data sug-
gest that NKG2D cross-linking leads to Ca2 mobili- 10 	g/ml (Figure 4C). Control F(ab
)2 had no effect,
even at 40 	g/ml. A similar response to MI-6 mAb waszation.
For functional analysis of NK cells and macrophages, observed with LAK cells from mutant mice lacking the
NK cell Fc receptor (FcRIII/ mice), effectively rulingit was important to avoid the possibility that the MI-6
mAb could engage Fc receptors on the cells, thus im- out the possibility that the response was due to residual
intact antibody in the F(ab
)2 preparation (Figure 4D).parting a directly stimulatory signal. Therefore, we em-
ployed MI-6 F(ab
)2 fragments for these experiments. The response of LAK cells to MI-6 mAb was similar
to the response to PK136, a mAb specific for the stimula-LAK cells or freshly isolated NK cells were stimulated
to produce IFN- by plate-bound MI-6 F(ab
)2 at coating tory receptor NKR-P1C (Karlhofer and Yokoyama, 1991).
Combining PK136 with a limiting dose of MI-6 F(ab
)2doses of 1 	g/ml or higher, reaching a maximum with
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ment. For unknown reasons, the percentage of NK cells
that secrete IFN- in response to PK136 or MI-6 gener-
ally reached a maximum of 10%–30% in these experi-
ments (Figure 4), and only 50%–80% of the cells re-
sponded even to pharmacologic agents (PMA plus
ionomycin) in most experiments (data not shown). A
substantial fraction of NK1.1CD3 cells are therefore
generally hyporesponsive to stimulation with these
agents, perhaps because they are immature or anergic.
To examine the responses of activated macrophages
to receptor stimulation, bone marrow macrophages
were precultured alone or with IFN-/ to induce NKG2D
expression and then transferred to wells coated with
MI-6 F(ab
)2 or control F(ab
)2. Macrophage stimulation
was assessed 2 days later in terms of either nitric oxide
(NO) production or TNF secretion. NKG2D cross-link-
ing resulted in substantial secretion of nitric oxide and
TNF, whereas wells coated with control F(ab
)2 had no
effect (Figure 4F). Control macrophages that had been
cultured in the absence of IFN-/, and therefore did
not express NKG2D, did not respond to stimulation by
MI-6 mAb (Figure 4F). The requirement for receptor in-
duction argues against the possibility that macrophage
activation was due to LPS or other possible contami-
nants in the anti-NKG2D antibody preparation. Similar
results were obtained with thioglycollate-induced peri-
toneal macrophages (data not shown). Cross-linking
with MI-6 F(ab
)2 also enhanced a basal level of NO
production that was induced by LPS or IFN- (data not
shown).
To investigate whether MI-6 mAb stimulates activated
CD8 T cells, we generated a CD8 T cell line specific
for the LCMV GP33 peptide. These cells expressed uni-
formly high levels of NKG2D (data not shown). In con-
trast to the results with NK cells, MI-6 failed to mediate
redirected lysis of Daudi target cells by activated CD8 T
cells, suggesting that NKG2D does not directly stimulate
CD8 T cells (Figure 5A). Furthermore, the activated
Figure 4. Cross-Linking of NKG2D with MI-6 mAb Is Sufficient to CD8 T cells did not respond to receptor cross-linking
Activate NK Cells and Macrophages
by producing IFN- or by fluxing Ca2 (Figures 5B and
Data are representative experiments of at least three performed.
5C). All three types of responses were induced by control(A) MI-6 mAb enhances lysis of FcR Daudi target cells by NK1.1
anti-CD3 or anti-TCR mAbs (Figures 5A–5C). In addi-LAK cells in a redirected lysis assay.
tion, cross-linking of the NKG2D receptor alone failed(B) Addition of an anti-rat F(ab
)2 cross-linking antibody to NK1.1
LAK cells coated with the MI-6 antibody induced rapid calcium flux. to stimulate proliferation of CFSE-labeled CD8 T cells
No calcium flux was seen with control antibody. (Figure 5D). The same T cells responded well to anti-
(C and D) Plate-bound F(ab
)2 fragments of MI-6 induce IFN- pro- CD3 mAb (Figure 5D). Although MI-6 mAb was not suffi-
duction by LAK cells, freshly isolated NK cells, and LAK cells from
cient to stimulate CD8 T cell proliferation, it did aug-FcR/ mice. Day 4 LAK cells or splenocytes from poly (I:C) pre-
ment the response of CD8 T cells to limiting doses oftreated mice were analyzed. The cells were stained for intracellular
anti-TCR mAb. The enhancement in proliferation wasIFN- while gating on NK1.1 CD3 cells.
(E) The level of stimulation with MI-6 mAb is comparable to that most marked for cells undergoing three or more cell
with PK136 (anti-NKR-P1C). Addition of limiting (3 	g/ml) doses of divisions. Anti-CD28 mAb tested in parallel behaved
MI-6 mAb to cells stimulated with PK136 enhanced the response nearly identically (Figure 5D). Thus, whereas NKG2D
only slightly.
cross-linking with MI-6 mAb provides a sufficient signal(F) Stimulation through NKG2D activates macrophage effector func-
for activation of NK cells and macrophages, it providestions. Bone marrow macrophages were precultured for 2 days with
instead an enhancing or costimulatory signal for activa-IFN-/ to induce NKG2D expression and then stimulated for an-
other 2 days with plate-bound F(ab
)2 fragments of MI-6 mAb or tion of NKG2D CD8 T cells.
control Ig. Secreted nitrite (indicating nitric oxide) or TNF was
assayed in the culture supernatants.
The NKG2D Receptor Mediates Natural Killing
of Tumor Cells
To test the efficacy of MI-6 mAb in functionally blockingenhanced the response only slightly compared to the
response to PK136 alone (Figure 4E), suggesting that the NKG2D-ligand interaction, we employed two tumor
cell lines that do not express NKG2D ligands and com-NKG2D engagement does not provide significant costi-
mulatory activity in conjunction with NKR-P1C engage- pared them to retroviral transductants that express high
Immunity
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Figure 6. NKG2D Ligand-Induced NK Cell Activation Is Blocked by
MI-6 mAb
Figure 5. NKG2D Cross-Linking Costimulates, but Does Not Stimu- (A) MI-6 mAb (50 	g/ml) blocks NKG2D-dependent killing by LAK
late, CD8 T Cells cells of target cells transduced to express H60 or Rae1 ligands.
RMA cells (top) were not killed unless the cells were transducedRepresentative experiments of at least two are shown. Each analysis
with NKG2D ligands, and MI-6 mAb blocked the induced level ofwas performed in other CD8 T cell lines with similar results.
killing completely. B16-BL6 cells (bottom) lacking NKG2D ligands(A) MI-6 antibody fails to redirect cytotoxicity of FcR Daudi cells
were sensitive to NK cells, but H60 or Rae1 transduction enhancedby a CD8 T cell line specific for the LCMV-derived peptide GP33,
their sensitivity. The ligand-dependent component was blocked byunlike control anti-CD3 mAb.
MI-6 mAb. Control Ig was added to the control assays. Standard(B and C) Activated NKG2D CD8 T cells (a line specific for LCMV)
deviations are shown, but in most cases are too small to visualizedo not produce IFN- (B) or flux calcium (C) in response to NKG2D
in the figure. A representative analysis of six is shown.cross-linking, but do respond to anti-TCR mAb. Nearly 40% of
(B and C) MI-6 mAb (50 	g/ml) blocked IFN- secretion by LAK cellsNK1.1 LAK cells responded in a parallel test (data not shown). A
(B) or freshly isolated NK cells (C) induced by H60 or Rae-transducedrepresentative experiment of three performed is shown.
cells. Control Ig was added to the control assays. IFN- production(D) NKG2D cross-linking costimulates T cell proliferation. CFSE-
was visualized by intracellular staining after 5 hr of stimulation.labeled, activated NKG2D CD8 T cells (a line specific for LCMV)
Representative analyses of three (LAK cells) or two (NK cells) arewere stimulated for 4 days with plate-bound anti-TCR in combina-
shown. N.D., not done.tion with a constant dose (9 	g/ml) of plate bound MI-6 mAb (top)
or anti-CD28 mAb (bottom). MI-6 mAb enhanced CD8 T cell prolif-
eration to a comparable extent as did anti-CD28 mAb. Costimulation
levels of the ligands. As reported previously (Diefenbachis most pronounced in the case of cells undergoing three or more
divisions (right panels). et al., 2001), RMA cells are resistant to NK cells, but
RMA cells transduced with Rae1 or H60 are rendered
NKG2D, Natural Killing, and Cell Activation
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sensitive to NK cells (Figure 6A). MI-6 F(ab
)2 but not
control F(ab
)2 blocked the ligand-dependent killing to
background levels. B16-BL6 melanoma cells also lack
NKG2D ligands, yet these cells are killed by NK cells,
suggesting the involvement of other stimulatory recep-
tor interactions (Figure 6A). Transduction of B16-BL6
with Rae1 or H60 significantly enhanced killing by NK
cells, and MI-6 F(ab
)2 blocked the enhanced level of
killing, but not the ligand-independent component of the
killing (Figure 6A). MI-6 F(ab
)2 also specifically blocked
IFN- production by LAK cells and NK cells that had
been stimulated with ligand-transduced RMA or B16
tumor cells (Figures 6B and 6C). Thus, MI-6 mAb is
highly efficacious in specifically blocking NKG2D-ligand
interactions without interfering with other natural killing
recognition systems.
Notably, untransduced B16 cells failed to stimulate
significant IFN- production by NK cells compared to
the response with no stimulator cells, despite the fact
that these cells were quite sensitive to NK killing (com-
pare Figures 6A and 6B). This may reflect a requirement
for more intense stimulation for cytokine production as
opposed to killing, a phenomenon that has been pre-
viously documented with CD8 T cells (Valitutti et al.,
1996).
A majority of tumor cell lines that have been previously
examined express NKG2D ligands (Diefenbach et al.,
2000). To detect NKG2D ligand expression, NK-sensitive
tumor cell lines of B6 and BALB/c origin were stained
with a previously described soluble tetrameric NKG2D
reagent (Diefenbach et al., 2000). Two of the cell lines
(B16 and RMA/S) failed to stain, whereas eight of the
cell lines stained well with NKG2D tetramers but not
with control tetramers (Figure 7A). Each cell line was
tested as a target cell for NK cells in the presence of
a predetermined excess dose of MI-6 mAb or control
antibody. The NK cells were from B6 mice for the B6
tumor cells or from BALB/c mice for the BALB/c tumor
cells. In the case of the cell lines that lack NKG2D li-
gands, the killing curves with MI-6 mAb and control
antibody were superimposable, indicating that NKG2D
binding by the antibody does not impart any inhibitory
effect in the absence of ligands (Figure 7B). In contrast,
partial inhibition of NK killing by MI-6 mAb was evident
with all eight cell lines that expressed NKG2D ligands
(Figures 7C and 7D). Addition of more antibody did not
lead to greater inhibition (data not shown). The results
indicate that for most tumor target cells, recognition
leading to natural killing is mediated to a significant
B16 and RMA/S tumor cell lines were among the few tumor lines
tested that did not express ligands for NKG2D.
(B) MI-6 mAb (50 	g/ml) did not influence killing by LAK cells of
susceptible cell lines that do not express NKG2D ligands.
(C and D) MI-6 mAb (50 	g/ml) partially blocks lysis by LAK cells of
B6-derived (C) or BALB/c-derived (D) tumor target cells that naturally
express NKG2D ligands. The antibody was in excess, as this dose
was sufficient to completely block lysis of transduced target cells
expressing higher levels of NKG2D ligands (Figure 6). Furthermore,
Figure 7. NKG2D Participates in Natural Killing of Target Cells that addition of higher antibody doses did not increase the level of inhibi-
Naturally Express NKG2D Ligands tion (data not shown). Standard deviations are shown, but in most
(A) NKG2D ligand expression was visualized by staining with NKG2D cases are too small to visualize in the figure. A representative analy-
tetramers (shaded) versus control irrelevant tetramers (open). The sis of three is shown.
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degree by NKG2D, but that other receptor-ligand sys- T cells, which express abundant cell surface NKG2D.
Cross-linking of NKG2D did enhance proliferation oftems also play an important role. These other recogni-
tion systems presumably also account for the NK-sensi- CD8 T cells induced by T cell receptor cross-linking,
in line with evidence that human NKG2D provides pri-tivity of certain NKG2D-ligand-negative tumor target cell
lines, such as B16 and RMA/S (Figure 7). marily a costimulatory signal for T cells (Groh et al.,
2001). Thus, our results suggest that NKG2D signals
differently in distinct immune cell types. It will be ofDiscussion
interest to determine the molecular basis for these differ-
ences in signaling.Stimulatory NK cell receptors specific for MHC mole-
Results with the MI-6 mAb confirmed our earlier find-cules have been characterized previously, but much evi-
ings that activated mouse macrophages expressdence suggests that natural killing of most tumor target
NKG2D (Diefenbach et al., 2000). Furthermore, wecells is mediated by non-MHC-specific receptors (re-
showed that receptor expression is induced not only byviewed in Moretta et al., 2001). Our results provide direct
LPS, but also by IFN-/ or IFN-, but not by TNF.evidence that NKG2D and its ligands represent one such
Notably, all of these NKG2D-upregulating agents arerecognition system employed by NK cells to attack tu-
involved as mediators or effector molecules in the innatemor cell lines. Excluding the MHC-specific receptors,
immune system, suggesting that NKG2D upregulationNKG2D is the only receptor involved in natural killing
by macrophages is likely to be an accompaniment offor which ligands have been identified. The results also
innate immune responses. The additional finding thatindicate, however, that additional receptor-ligand sys-
NKG2D engagement is sufficient to trigger certain mac-tems participate in natural killing. Studies of human NK
rophage effector functions supports the possibility thatcells have implicated several other stimulatory receptors
the receptor plays a role in macrophage responses inin natural killing, including NKp46, NKp30, and NKp44
vivo. The full spectrum of macrophage functions in-(Moretta et al., 2001; Pende et al., 2001). A functional
duced or regulated by NKG2D engagement remains tohomolog of NKp46 has been identified in mice. Evidence
be investigated.suggests that NKR-P1 receptors also play a role in natu-
NKG2D is also expressed by subsets of NK1.1 T cellsral killing of some tumor cells (Ryan et al., 1995). The
and  T cells. Interestingly, all NK1.1 T cells expressinvolvement of multiple receptor-ligand systems in natu-
CD44, and expression of NKG2D by  T cells is limitedral killing is reminiscent of other recognition systems of
to the CD44 subset, suggesting the NKG2D expressionthe innate immune system, such as the Toll-like receptor
by T cells is related to previous activation or acquisitionsystem, in which the various isoforms recognize differ-
of a memory phenotype. On the other hand, not allent molecular patterns associated with pathogens. In
NK1.1 T cells or CD44  T cells express NKG2D.the case of NK cells, however, NKG2D (and possibly the
Most striking was the finding that intestinal epithelial other receptors as well) recognize self-ligands that are
T cells, despite expressing CD44 and being chronicallyinduced by transformation, infection, and/or cellular
activated in vivo, do not express NKG2D. In contrast,stress.
TCR DECs in the skin uniformly express NKG2D. ItAnother significant finding of our study is that cross-
is possible that some  subtypes vary in their capacitylinking of NKG2D with immobilized mAb is a sufficient
to express NKG2D, just as is seen for CD8 versussignal to trigger NK cells and macrophages, demonstra-
conventional CD4  T cells. Alternatively, factors inting that NKG2D is a directly stimulatory receptor in
addition to previous activation may control NKG2D ex-these cell types. This in turn suggests that upregulation
pression by  T cells. Further studies will be necessaryof NKG2D ligands by a tumor cell or other cell is likely
to determine whether NKG2D expression is determinedto be sufficient for targeting of the cell by NK cells and
by the activation state, developmental state, or otheractivated macrophages. The results are not readily com-
determinants. In this vein, however, it was of interestpatible with the notion that NKG2D delivers signals only
that memory CD8  T cells maintained high levels ofthrough its interaction with a costimulatory adaptor mol-
NKG2D even months after priming. An intriguing possi-ecule. Previous studies have shown that other costimu-
bility is that NKG2D plays a role in the rapid and effica-latory receptors containing the YxxM motif, such as
cious recall response of memory CD8 T cells and possi-CD28, fail to stimulate either Ca2 mobilization or ef-
bly of other types of memory T cells.fector functions (Tsuchihashi et al., 2000). It remains
possible that DAP10 is not solely involved in costimula-
Experimental Procedurestion and can deliver directly activating signals in certain
cellular contexts. Alternatively, NKG2D may interact with
Mice
other signaling molecules in addition to DAP10. C57Bl/6 (B6) and BALB/c mice were obtained from Jackson Labora-
In contrast to our results with mouse NK cells, it was tory. OT-1 transgenic mice (Hogquist et al., 1994) on a C57Bl/6
reported that human NK cells are not directly activated background were provided by James Allison. FcRIII/ mice (Ujike
et al., 1999), which had been backcrossed once to C57Bl/6 mice,by immobilized anti-NKG2D antibody (Wu et al., 2000).
were a generous gift of Jeffrey Ravetch (Rockefeller University).It is therefore possible that NKG2D signals differently in
human versus mouse NK cells. Alternatively, the distinct
The NKG2D Monoclonal Antibodyresults may reflect experimental differences, such as
Lewis Rats were injected four times at 2 week intervals with CHOthe use of an NK cell line in the human studies or the
cells expressing a fusion protein consisting of the extracellular por-
use of different concentrations of anti-NKG2D antibody. tion of NKG2D and the transmembrane and cytoplasmic portions
Interestingly, NKG2D cross-linking was not directly of Ly49A. Three days after the last immunization, splenocytes were
fused to the P3X8653 fusion partner as described elsewhere (Coli-stimulatory in the case of preactivated mouse CD8
NKG2D, Natural Killing, and Cell Activation
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gan et al., 1991). Hybridoma supernatants were screened for anti- or control F(ab
)2 followed by biotinylated donkey anti-rat F(ab
)2
fragment specific F(ab
)2 fragments (Jackson Immunoresearch),body that stained NKG2D-transfected CHO cells but not untrans-
fected CHO cells. A positive hybridoma, MI-6, was expanded and which were detected with streptavidin PE (Molecular Probes). In
some experiments, the MI-6 mAb was preincubated with a 10-foldsubcloned four times. The MI-6 mAb is an IgG2a/, as determined
with a mAb-based rat Ig isotyping kit (Pharmingen, San Diego, CA). molar excess of recombinant NKG2D protein.
For analysis of LCMV-specific T cells, splenocytes were stainedMI-6 mAb stained NKG2D-transfected Chinese hamster ovary (CHO)
cells, but did not stain CHO cells transfected with NKG2A/CD94, in four steps: (1) unconjugated MI-6 mAb (40 	g/ml) or isotype
control mAb; (2) donkey F(ab)2 anti-rat IgG-FITC (Jackson Immuno-NKG2C/CD94 (see Supplemental Figure S1 at http://www.immunity.
com/cgi/content/full/17/1/19/DC1), or NKG2E/CD94 (data not research); (3) normal rat serum to block free Ab sites; (4) anti-
CD8-tricolor (CalTag) and class I tetramers multimerized with PE-shown), in line with the fact that these other NKG2 family members
exhibit less than 40% sequence identity with NKG2D, despite their streptavidin (Molecular Probes). Staining with NKG2D tetramers was
as previously described (Diefenbach et al., 2000). Tetrameric com-similar names. In addition, MI-6 mAb failed to react with 14 other
NK cell receptors tested, including Ly49A-I, NKRP-1A-D, and CD69 plexes of Db bound with LCMV-derived peptides GP33–41 and NP396–404,
were prepared as described previously (Murali-Krishna et al., 1998).(data not shown).
MI-6 hybridoma supernatant was collected from an INTEGRA After staining, cells were fixed with 1% formaldehyde. All flow cy-
tometry was performed on EPICS XL-MCL machines (Coulter, Hia-CELLine CL1000 (Integra Biosciences, Switzerland) cell cultivation
system. The mAb was purified by precipitation with 45% saturated leah, FL), and data were analyzed with FlowJo software (Tree Star,
Stanford University).ammonium sulfate followed by gel filtration chromatography with a
Superdex 200 column on an FPLC system. MI-6 mAb was biotinyl-
ated using EZ-Link NHS-LC-Biotin (Pierce, Rockford, IL). Cellular Stimulation by Anti-NKG2D mAb
F(ab
)2 fragments were prepared using immobilized pepsin For redirected lysis assays, effector cells were incubated with 100
(Pierce) according to the manufacturer’s instructions. No intact anti- 	g/ml antibody for 45 min. 51Cr-labeled Daudi cells were then added
body was detected by SDS-PAGE after pepsin digestion. After purifi- to the wells for 4 hr. To assay calcium mobilization, cells were
cation of F(ab
)2 fragments by size exclusion chromatography, no labeled with 3 	M INDO-1AM and pluronic detergent (Molecular
Fc fragments or intact antibody were detected by SDS-PAGE, nor Probes) according to manufacturer’s instructions. Effector cells
did an anti-rat Fc reagent stain cells incubated with the F(ab
)2 were incubated with primary antibody on ice for 30 min, washed,
reagent. Polyclonal rat IgG F(ab
)2 (Jackson Immunoresearch, West- and run for 5 min at 37C on a Coulter Elite-ESP (Miami, FL). Cross-
grove, PA) was used as a control. linking F(ab
)2 anti-rat IgG antibody was added after 40 s of data
collection. Induction of IFN- production was performed in round
Cell Preparations bottom high-protein binding plates (Costar, Fischer Scientfic, Pitts-
Splenic NK cells from untreated or poly (I:C)-treated B6 mice were burg, PA) that had been coated overnight at 4C with the indicated
enriched by depleting B cells with anti-CD24 (mAb J11d) antibody concentrations of intact mAb or F(ab
)2 fragments, as indicated, in
and Low-tox H complement (Cedarlane Laboratories, Ontario, Can- 20	l PBS, followed by four rinses with 200	l PBS. The IFN- release
ada), followed by centrifugation in Lympholyte-Mammalian M (Ce- assay was done using Cytofix/Cytoperm intracellular staining kits
darlane Laboratories). Lymphokine activated killer (LAK) cells were (Pharmingen). For analysis of NK cells, 1  105 LAK cells, or spleno-
prepared by incubating B6 splenocytes for 4 days in medium con- cytes isolated from poly(I:C)-injected mice that had been enriched
taining 1 	g/ml IL-2. In the calcium flux and redirected lysis experi- for NK cells by treatment with anti-HSA and complement, were
ments, LAK cells were 97% NK1.1 following depletion of CD8, incubated in each well for 5 hr in the presence of Golgi Plug before
CD4, TCR /, and CD19 cells using the AutoMACS (Miltenyi transfer to V-bottom plates and staining for surface NK1.1, CD3, and
Biotec, Auburn, CA) according to manufacturer’s instructions. intracellular IFN-. Results represent percent of gated NK1.1CD3
Fetal NK cells were enriched from fetal day 15 thymocytes by cells.
treatment with anti-CD24 and complement (Carlyle and Zu´n˜iga- For analysis of T cell activation by anti-NKG2D, we established a
Pflu¨cker, 1998). Dendritic epidermal cells (Sullivan et al., 1985) and CTL line specific for the modified LCMV peptide GP33M (KAVYNFATM)
intestinal IELs (Chu et al., 1999) were prepared as described. Bone in the context of Db. Splenocytes from mice infected 8 days before
marrow macrophages were differentiated in L cell culture superna- with LCMV were cultured with irradiated B6 splenocytes pulsed with
tant for 5 days before use (Portnoy et al., 1988). 1 	M GP33M peptide and restimulated weekly. The medium was
supplemented with 5% T-STIM (BD, Franklin Lakes, NJ) beginning
at the third stimulation. Seven days after the last restimulation, 1 NKG2D Upregulation
105 cells were incubated in triplicate in wells that had been coatedFor analysis of NKG2D upregulation in T cells, enriched splenic T
at 4C overnight with MI-6 mAb, anti-CD28 mAb, or control Ig, alonecells were stimulated in 96-well plates that had been coated over-
or in combination with anti-TCR mAb. Two days later, Golgi Plugnight at 4C with 5–10 	g/ml anti-TCR antibody (H57-597) (Kubo et
was added for 5 hr before staining and analysis of intracellular IFN-al., 1989). Alternatively, unfractionated splenocytes from OT-1 TCR
as described for NK cells. For proliferation studies, the cells weretransgenic mice were incubated with irradiated C57Bl/6 splenocytes
preincubated for 10 min in 0.5 	M CFSE, quenched with FCS, andthat had been pulsed with the cognate peptide (SIINFEKL). For
washed three times in RPMI media with 10% FCS. After 4 days withanalysis of NKG2D upregulation in vivo on T cells, mice were infected
plate-bound antibody, cells were counterstained with propidiumwith 2  105 PFU of LCMV (Armstrong CA1371 strain) for primary
iodide and analyzed by flow cytometry. Separate analysis indicatedresponses or 2  106 PFU for secondary responses (which occurred
that all the cells were CD8 T cells. For analysis of macrophageat least 1 month after clearance of the primary infection). To examine
activation, the cells (see Cell Preparations) were preincubated forNKG2D upregulation in macrophages, the cells (see Cell Prepara-
48 hr with or without 1000 U/ml IFN-/, washed, and incubated intions) were stimulated for 24–72 hr with 20 ng/ml LPS (Sigma-Aldrich,
triplicate at 1  105 per well in 96-well plates that had been coatedSt. Louis, MO), 10 ng/ml IFN- (R&D Systems, Minneapolis, MN),
with MI-6 or control F(ab
)2. After 48 hr, nitrite accumulation was1000 U/ml IFN-/, or 1 ng/ml TNF (R&D Systems).
determined with the Griess reagent as described (Diefenbach et al.,
2000), and secreted TNF was determined in a bioassay using themAbs, Tetramers, and Staining Protocols
TNF-sensitive cell line WEHI 164/cl.13 (Espevik and Nillsen-Meyer,We employed PK136-FITC (anti-NK1.1), anti-CD3 TC, anti--FITC,
1986).anti-CD44-TC, anti-V2-FITC, anti-IFN--FITC (Pharmingen), anti-
HA-FITC (CoVance, Berkeley, CA), anti-CD8 and anti-CD4 (Caltag,
Burlingame, CA), anti-TCR (H57-597), anti-CD28 (37N.51) (a gift of Northern Blots
BM macrophages were left unstimulated or were stimulated for 48James Allison), anti-rat IgG-FITC (Jackson Immunoresearch). Cells
were incubated in 96-well plates for 30 min with MI-6-biotin, followed hr with either 20 ng/ml LPS (Sigma-Aldrich), 10 ng/ml IFN- (R&D
Systems), 1000 U/ml IFN-/, or 1 ng/ml TNF (R&D Systems). RNAby washing and incubation with streptavidin PE (Molecular Probes,
Eugene, OR) in combination with relevant antibodies as indicated was prepared using TRIZOL reagent (Invitrogen, Carlsbad, CA) fol-




formed as described elsewhere (Maniatis et al., 1989). Blots were stimulate NK cytotoxicity through the NKG2D receptor. Immunity
14, 123–133.hybridized with a [-32P]CTP-labeled full-length NKG2D cDNA probe.
The blots were washed at 65C in 0.5 SSC/1% SDS. After autoradi- Dennert, G., Landon, C., Lord, E.M., Bahler, D.W., and Frelinger,
ography, the blot was stripped and rehybridized with a 32P-labeled J.G. (1988). Lysis of a lung carcinoma by poly I:C-induced natural
-actin probe. killer cells is independent of the expression of class I histocompati-
bility antigens. J. Immunol. 140, 2472–2475.
Inhibition of Target Cell Recognition by MI-6 mAb Diefenbach, A., and Raulet, D.H. (2001). Strategies for target cell
LAK cells, titrated in triplicate in 96-well plates, were preincubated recognition by natural killer cells. Immunol. Rev. 181, 170–184.
for 30 min with 50 	g/ml MI-6 mAb, rat IgG, or medium alone before
Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N., and Raulet,addition of 51Cr-labeled target cells (1  104 ) for 4 hr (Liao et al.,
D.H. (2000). Ligands for the murine NKG2D receptor: expression1991). Comparable results were obtained with intact mAb and F(ab
)2
by tumor cells and activation of NK cells and macrophages. Nat.fragments. In Figure 7, RMA, B16, RMA/S, MC38, LLC, and NOBO-1
Immunol. 1, 119–126.were blocked with F(ab
)2 fragments, while TRAMP, YAC-1, 3T3
Diefenbach, A., Jensen, E.R., Jamieson, A.M., and Raulet, D.H.(BALB/c), SM-1, and WEHI-164 were blocked with intact mAb. Addi-
(2001). Rae1 and H60 ligands of the NKG2D receptor stimulate tu-tion of twice as much antibody gave identical results, indicating that
mour immunity. Nature 413, 165–171.the reagent was in excess.
For analysis of IFN- production, LAK cells or enriched splenic NK Espevik, T., and Nillsen-Meyer, J. (1986). A highly sensitive cell line,
cells were preincubated with F(ab
)2 fragments of MI-6 as described WEHI164 subclone 13, for measuring cytotoxic factor/tumor necro-
above and then incubated with target cells at a 1:1 ratio for 5 hr in sis factor from human monocytes. J. Immunol. Methods 95, 99.
the presence of Golgi Plug before staining for intracellular IFN-,
Girardi, M., Oppenheim, D.E., Steele, C.R., Lewis, J.M., Glusac, E.,
NK1.1, and CD3 as described above.
Filler, R., Hobby, P., Sutton, B., Tigelaar, R.E., and Hayday, A.C.
(2001). Regulation of cutaneous malignancy by gammadelta T cells.
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